Hospitals' Hang-Ups With Point-Of-Care Testing
The hospital market for point-of-care testing represents a conundrum for manufacturers. Demand for it is growing--but, with the exception of glucose monitoring, not as fast as proponents had expected. A recent survey of a third of US hospitals with 150 or more beds seeks to gather information about hospital point-of-care testing utilization and preferences.
You may also be interested in...
The in vitro diagnostics industry has looked for years to point-of-care testing in hospitals as a growth segment. The premise is sound--easy-to-use tests performed near the patient will yield faster results that enable physicians to make better on-the-spot treatment decisions. In reality, hospital demand is increasing, but not as fast as expected. A recent survey of one-third of US hospitals with 150 beds or more, by Enterprise Analysis Corp. seeks to understand POCT usage and demand trends.
Abbott Laboratories' acquisition of i-Stat for $392 million reflects the promise and limitations of point-of-care diagnostics. A decade ago, i-Stat was a giddy startup, on a mission to revolutionize laboratory medicine with a handheld diagnostics system that could run basic blood tests rapidly at the patients' bedside. While it has accomplished much, it is far from creating a revolution. Meanwhile, the timing of the deal comes as Abbott emerges from a four-year nightmare with the FDA in which the FDA forced it to pull many of its important immunoassay tests off the market.
I-Stat, the pioneer in point-of-care diagnostics, is paying Abbott $60 million to break off a five-year-old distribution arrangement. That's a lot of money for a company that lost close to $60 million last year and has never made a dime. But i-Stat executives say it's the only way for their company to thrive and become profitable. The deal with Abbott never reached hoped-for sales goals, although Abbott met minimum targets. I-Stat has spent the better part of the past year shoring up its executive management team and building a sales and marketing infrastructure so that it can hit the ground running when the deal terminates in December.